Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson’s Disease?

  title={Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson’s Disease?},
  author={Christopher J. Barnum and Mal{\'u} G{\'a}mez Tansey},
  journal={Current Neurology and Neuroscience Reports},
  • C. BarnumM. Tansey
  • Published 12 May 2012
  • Biology
  • Current Neurology and Neuroscience Reports
Generally speaking, inflammation as a key piece to the Parkinson’s disease (PD) puzzle is a relatively new concept. Acceptance of this concept has gained ground as studies by various researchers have demonstrated the potential of mitigating nigral cell death by curtailing inflammation in animal models of PD. We propose that the significance of inflammation in PD pathology may extend beyond the nigrostriatal region. In the current review, we present an argument for this based on the Braak… 

Proinflammatory cytokines in Parkinson’s disease and current treatment approaches

The relationship of proinflammatory cytokines with the pathology of Parkinson's disease is discussed and current treatment approaches targeting these mechanisms are evaluated.

Role of Microgliosis and NLRP3 Inflammasome in Parkinson’s Disease Pathogenesis and Therapy

The role and relation of both the inflammasome and microglial activation with the pathogenesis, symptoms, progression and the possibilities for new therapeutic strategies in PD are described.

l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

It is proposed here that the significance of inflammation in PD may go beyond the nigral cell death, and the key aims of current PD research ought to be to elucidate the time sequence in which the inflammatory factors act in PD patient brain and the mechanisms by which neuroinflammatory response contributes to the collateral effects of l‐DOPA treatment.

Inflammatory response in Parkinson's disease (Review).

This review will discuss the current knowledge regarding inflammation and review the roles of intracellular inflammatory signaling pathways, which are specific inflammatory mediators in PD, and possible therapeutic strategies are proposed.

Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's disease.

Novel potential pharmacological therapeutic strategies focusing on cannabinoids, caffeine, melatonin, and dietary compounds, which could act as adjuvants to regular PD therapy are discussed.

Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson’s disease

Sex-dependent sensitivity to MPTP revealed a sexually dimorphic inflammatory response to chronic MPTP treatment and suggest that males may have higher vulnerability than females to inflammation-induced degeneration, which has significant implications for therapeutic development of inflammatory targets in the clinic.


There were found correlations between severity of depressive symptoms and age of PD onset, and levels of cytokines in serum and CSF, suggesting Neuroinflammation may participate in development of depressive Symptoms at PD.



Modeling neuroinflammatory pathogenesis of Parkinson's disease.

Inflammation as a causative factor in the aetiology of Parkinson's disease

  • P. Whitton
  • Biology
    British journal of pharmacology
  • 2007
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting mainly the elderly, although a small proportion of PD patients develop the illness at a much younger age. In the former

Glial reactions in Parkinson's disease

  • P. McgeerE. Mcgeer
  • Biology
    Movement disorders : official journal of the Movement Disorder Society
  • 2008
This review concentrates on glial reactions in PD and indicates that an acute insult to the SN can result in a sustained local inflammation, and the α‐synuclein model indicates that a endogenous protein can induce inflammation and, when overexpressed, can lead to autosomal dominant PD.

Parkinson's disease: a dual‐hit hypothesis

It is concluded that the most parsimonious explanation for the initial events of sporadic Parkinson's disease is pathogenic access to the brain through the stomach and nose – hence the term ‘dual‐hit’.

The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.

Data are consistent with a growing body of literature that implicates inflammatory cytokines in neural and behavioral processes and further suggests that TNF-α may be involved in the production and/or maintenance of non-motor symptoms in PD.

Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration

The studies suggest that loss of Parkin function increases the vulnerability of nigral DA neurons to inflammation-related degeneration, which may enable identification of early biomarkers of degeneration and aid in preclinical screening efforts to identify compounds that can halt or delay the progressive degeneration of the nigrostriatal pathway.